Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
- 10 April 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (11), 2502-2512
- https://doi.org/10.1200/jco.2005.12.157
Abstract
Purpose This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies. ...Keywords
This publication has 29 references indexed in Scilit:
- Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene, 2002
- AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survivalOncogene, 2002
- The EGF receptor family as targets for cancer therapyOncogene, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Epidermal growth factor receptors: critical mediators of multiple receptor pathwaysCurrent Opinion in Cell Biology, 1999
- Convergence of Progesterone and Epidermal Growth Factor Signaling in Breast CancerPublished by Elsevier BV ,1998
- ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization PartnerMolecular and Cellular Biology, 1998
- A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth FactorMolecular and Cellular Biology, 1996
- Tyrosine Phosphorylation of Cbl upon Epidermal Growth Factor (EGF) Stimulation and Its Association with EGF Receptor and Downstream Signaling ProteinsPublished by Elsevier BV ,1996
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989